Eli Lilly and Novo Nordisk Rose After the FDA’s Vision Warning
When a label change dents sentiment, not the franchise
When a label change dents sentiment, not the franchise
Tuesday’s half-year numbers will test Germany and cash flow cover.
The first investor call since swallowing Warner Bros. Discovery will show whether the integration plan can actually service what it…
Phase 1b data for CTX310 hit Monday morning at AHA, with the big question: can one IV infusion scale into…
iPhone 18 Pro demand looks solid. The December guide moves the stock.
Mounjaro and Zepbound topped $16B in Q3. Is it priced in?
A four-session pattern in Nasdaq names looks like an AI capex verdict, but month-end pension flows and a midterm countdown…
Power & Energy orders are converting. Whether tariffs are eating the profit is what Q3 just answered.
Reports say Ambarella is in a late-stage auction. AMD is not listed.
A 21% listing pop is the easy money. Whether Jio can close the gap on Airtel's per-user revenue is the…